News | Heart Failure | October 03, 2022

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home 

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home

October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced two poster presentations, including a late breaker, at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, which is being held September 30 – October 3, in Washington DC. 

“We are very pleased to have an opportunity to present scientific data at this year’s HFSA Annual Scientific Meeting, which is among the most important and well attended gatherings of heart failure experts each year,” stated John Tucker, chief executive officer of scPharmaceuticals. “The two presentations highlight the significant potential benefits – both to patients and payers – of an alternative approach to the management of congestion in patients with heart failure outside of the hospital. We believe FUROSCIX (furosemide injection), if approved, represents a potential new model for the treatment of congestion in patients with heart failure by allowing IV-equivalent diuresis at home, thus potentially reducing costly hospital admissions and readmissions.” 

“We are eagerly approaching our October 8 FUROSCIX PDUFA target action date, and, assuming FDA approval, are well prepared to initiate a robust commercial launch of FUROSCIX in 2022,” Tucker concluded. 

 

Details of the presentations are as follows: 

Title: 

Avoiding Treatment in Hospital with FUROSCIX to Manage Congestion in Heart Failure (AT HOME-HF) – A Pilot Study 

Poster #: 

LBA-007 (late breaking) 

Session: 

General Poster Viewing Session II 

Date: 

Saturday, October 1, 2022 

Time: 

12:45pm – 1:00pm EDT 

Location: 

Exhibit Hall ePoster Hub 

Summary: 

This poster describes the results of a Phase 2, multicenter, pilot study where 51 subjects presenting to a heart failure clinic with worsening congestion requiring augmented diuresis were randomized (2:1) to receive FUROSCIX or enhanced oral diuretics. 

Subjects who received FUROSCIX demonstrated augmented decongestion compared with patients receiving enhanced oral diuretics as demonstrated by: 

Improved diuresis as measured by a greater reduction in body weight from baseline at study day 3 (2.8 kg vs 0.8 kg, p=0.035); 

  • Improvement from baseline in mean 5-point dyspnea score at day 3 (-0.5 vs. 0.1, p=0.019); 
  • Greater number of patients with markedly or moderately better shortness of breath based on 7-point dyspnea at day 3 (44% vs 6%, p=0.006); 
  • Clinically relevant improvement from baseline in quality of life as measured by Kansas City Cardiomyopathy questionnaire – 12 (KCCQ-12) summary score at study days 7 and 30 of 8.9 points and 9.3 points, respectively; and 
  • An increase of 55.8 meters in the average six-minute walk distance at day 30 (36.7 vs -19.1 meters, p=.012). 

The win-ratio for the hierarchical endpoint of cardiovascular death, heart failure hospitalization, urgent ED/clinic visit for heart failure and the percentage change in NT-proBNP from baseline at day seven was 1.11 (95% Confidence Interval: 0.48-2.50) favoring the FUROSCIX group. 

During the 30-day study period, subjects in the FUROSCIX group spent an average of 23.2 days heart failure event free compared to 14.3 in subjects receiving enhanced oral diuretics. 

In the FUROSCIX group, 14.7% of subjects had a serum potassium level that was less than 3.5 mEq/L during the 30-day study and was managed effectively with oral potassium supplements. 

Conclusion: Subjects receiving subcutaneous FUROSCIX demonstrated augmented decongestion as evidenced by a greater reduction in body weight, better dyspnea scores, greater exercise capacity and improvement of health-related quality of life compared with patients receiving enhanced oral diuretics, or standard treatment in a phase 2, pilot study. The favorable results in the AT HOME-HF Pilot Study support conducting an adequately powered study. 

Title: 

Acute Decompensated Heart Failure: Examining Those with Brief Hospitalizations 

Poster #: 

291 

Session: 

General Poster Viewing Session IV 

Date: 

Sunday, October 2, 2022 

Time: 

12:30pm – 12:45pm EDT 

Location: 

Exhibit Hall ePoster Hub 

Summary: 

This poster describes a study that investigated the volume, length of stay (LOS) and patient characteristics of patients hospitalized for acute decompensated heart failure (ADHF) in the US using the multicenter National Inpatient Sample (NIS) representing approximately 20% of US acute care hospitals. Of the approximately 5 million discharges with any heart failure diagnosis code, 1.2 million patients had heart failure as the principal diagnosis code and approximately 43% of such patients had a LOS of less than 3 days (SLOS) with the average LOS being 2.2 days. Compared to patients with LOS greater than 3 days (LLOS), SLOS patients were less likely to require mechanical ventilation (2.8% vs 0.7%), dialysis (2.9% vs 0.4%) and undergo diagnostic procedures (70.4% vs 48.4%). SLOS patients were more likely to have a routine discharge to home (61.8% vs 39.7%) 

Conclusion: An alternative outpatient heart failure management may allow many patients to avoid the need for short hospitalizations with its potential complications and healthcare costs. 

For more information: www.scPharmaceuticals.com 


Related Content

News | Heart Failure

December 2, 2022 — Westchester resident, 62-year-old Miriam Nieves, is especially grateful this Thanksgiving season ...

Home December 02, 2022
Home
News | Heart Failure

December 2, 2022 — The U.S. Senate today passed the bipartisan Cardiovascular Advances in Research and Opportunities ...

Home December 02, 2022
Home
News | Heart Failure

December 1, 2022 — Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new ...

Home December 01, 2022
Home
News | Heart Failure

November 22, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with ...

Home November 22, 2022
Home
News | Heart Failure

November 21, 2022 — Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide ...

Home November 21, 2022
Home
News | Heart Failure

November 22, 2022 — Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

Home November 21, 2022
Home
News | Heart Failure

November 15, 2022 — Ten months after transplanting the first genetically-modified pig heart into a human patient ...

Home November 15, 2022
Home
News | Heart Failure

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

Home November 14, 2022
Home
News | Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

Home November 09, 2022
Home
News | Heart Failure

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

Home November 03, 2022
Home
Subscribe Now